1. Clinical study on the treatment of moderate to severe persistent allergic rhinitis by posterior nasal nerve combined with anterior ethmoid neurotomy.
- Author
-
Rongrong Wu, Lvhua Dong, Huajie Mao, Jianjun Wang, Dijiang Ma, and Jianing Sun
- Subjects
- *
ALLERGIC rhinitis , *NERVES , *SLEEP disorders , *QUALITY of life , *THERAPEUTICS - Abstract
Objectives: To investigate the clinical effect of posterior nasal nerve combined with anterior ethmoid neurotomy in the treatment of moderate to severe persistent allergic rhinitis. Methods: Thirty patients with moderate to severe persistent allergic rhinitis admitted to Linhai Second People’s Hospital from August 2019 to June 2020 were selected as subjects for prospective study and design. All patients underwent posterior nasal neurotomy and anterior ethmoid neurotomy simultaneously. Subsequently, the efficacy of all patients at 0.5 and one year postoperatively was compared. Their symptom score preoperatively and one year postoperatively as well as their preoperative and postoperative quality of life score were compared, and related adverse reactions were collected. Results: The curative effect ratio was 60% after 0.5 years and 90.0% after one year, showing a significant increase (χ²=12.000, P=0.007<0.05). The symptom score at one year postoperatively (1.15±0.32) was lower than that preoperatively (2.12±0.58), with a statistically significant difference (t=11.351, P=0.000<0.05); In terms of quality of life, nasal symptoms, ocular symptoms, practical difficulties, sleep disorders, emotional disorders and other symptoms were lower than those preoperatively, with statistically significant differences (P<0.05). Adverse reactions occurred in 4 patients (13.33%), but were eliminated after treatment. Conclusion: Posterior nasal nerve combined with anterior ethmoid neurotomy is a safe and reliable surgical method for the treatment of moderate to severe persistent allergic rhinitis, boasting a variety of benefits such as symptomatic relief, improved quality of life, and reduced adverse reactions, which is worthy of clinical promotion. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF